Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study

Clinical Pharmacology and Therapeutics
A ElisM Lishner

Abstract

Intravenous dobutamine administration improves short-term hemodynamics in patients with severe congestive heart failure (CHF). However, the clinical benefit of periodic administration remains controversial. To evaluate the efficacy of intermittent dobutamine administration in patients with refractory CHF. Nineteen patients with New York Heart Association class III/IV, ischemia-induced CHF participated in this double-blind, placebo-controlled study. All patients received intravenous dobutamine or placebo over a 24-hour period every 2 to 3 weeks for 6 months. They were also treated with angiotensin-converting enzyme inhibitors, digoxin, and diuretics. The number of admissions for CHF and mortality rate were compared. Ten patients received dobutamine and nine received placebo. The pretreatment characteristics were similar in both groups. No statistically significant difference was observed between the number of admissions for CHF (p = 0.11). The median survival after enrollment was 7.97 months in the placebo group and 4.6 months in the dobutamine group. The Kaplan-Meier survival curves overlay, with no statistically significant difference between the treatment arms (p = 0.7). Intermittent dobutamine infusions in patients with refr...Continue Reading

References

Nov 1, 1992·European Heart Journal·H H ErlemeierW Bleifeld
Nov 1, 1980·American Heart Journal·D V UnverferthC V Leier
Jun 1, 1982·Circulation·C V LeierD V Unverferth
May 1, 1995·Current Opinion in Cardiology·B M Massie, N B Shah
Dec 1, 1993·Circulation·P W Armstrong, G W Moe
Jan 1, 1993·Clinical Cardiology·A Om, M L Hess

❮ Previous
Next ❯

Citations

Dec 29, 2004·Cardiovascular Research·Euan A AshleyThomas Quertermous
Apr 25, 2003·Journal of Palliative Medicine·Michael W Rich, Bernard L Shore
Oct 11, 2014·Journal of Palliative Medicine·Mallory Strickland CiukszaGeorge Sokos
Aug 29, 2006·British Journal of Clinical Pharmacology·Atul PathakPhilippe van de Borne
Sep 20, 2005·Journal of the American College of Cardiology·Sharon Ann HuntUNKNOWN American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evalua
Sep 27, 2005·The Journal of Emergency Medicine·Sean P CollinsAlan B Storrow
Jul 20, 2005·Heart & Lung : the Journal of Critical Care·Jenny B Hamner, Kathy Jo Ellison
Sep 27, 2005·The American Journal of Cardiology·Melike BayramMihai Gheorghiade
Mar 21, 2002·Hospital Medicine·Andrew R W Money-Kyrle, Adam D Timmis
Jan 28, 2014·European Journal of Heart Failure·John Gierula, Klaus K A Witte
Feb 26, 2005·Circulation Journal : Official Journal of the Japanese Circulation Society·Mitsuru SuwaKazuteru Funahashi
Aug 19, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Eman HamadArthur M Feldman
Oct 25, 2007·Clinical Cardiology·David FeldmanRandell K Wexler
Apr 22, 2009·Current Cardiology Reports·Sarah M DonlanMihai Gheorghiade
May 1, 2010·Current Opinion in Cardiology·Barry CabuayDavid Feldman
May 11, 2010·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Lindsay M RyersonLara S Shekerdemian
May 17, 2003·Drugs & Aging·Kourosh MoazemiAbraham G Kocheril
Oct 25, 2006·Expert Opinion on Pharmacotherapy·Masao Endoh, Masatsugu Hori
Aug 22, 2000·Current Opinion in Cardiology·B Stanek, R Pacher
Jul 31, 2002·Heart Disease·James J Nawarskas, Joe R Anderson
Mar 22, 2003·Postgraduate Medicine·Francis Q Almeda, Steven M Hollenberg
Feb 18, 2016·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Wolfgang von ScheidtGeorg Ertl
Aug 30, 2016·Current Cardiology Reports·Danyaal S MoinJaved Butler
Sep 28, 2010·Heart Failure Clinics·Daniel J Penny, Giles Wesley Vick

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.